Bionova Scientific, an Asahi Kasei CDMO, formed a manufacturing alliance with Syenex, a genetic medicines platform company, designed to expand global access to DNA plasmids for next-generation gene delivery for advanced cell and gene therapies.
According to Darren Head, president of Bionova Scientific, at the core of Bionova’s plasmid DNA technology is its genetically stable cell line platform that has been engineered to eliminate insertion sequence elements (ISEs), cryptic prophages, and nonessential bacterial genomic regions. This IS-free host architecture significantly reduces plasmid rearrangements, deletions, and genetic instability, the “key risks that can compromise downstream lentiviral vector yield, batch-to-batch consistency, and regulatory robustness.”
When combined with Bionova’s plasmid DNA manufacturing processes, the platform delivers reproducible plasmids suitable for use in all genetic medicine formats, including LVV production or for mRNA manufacturing as DNA templates, he adds.
Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms. In parallel, Bionova expands its off-the-shelf and custom LVV plasmid system offerings, including gag/pol, rev, VSV-G, and transgene backbones, available from R&D through GMP.
“By integrating Syenex’s next-generation delivery technologies into our development and manufacturing platform, we are strengthening lentiviral vector plasmid systems used today, [while] also positioning our clients for a smoother transition to next-gen approaches like in vivo LVV.”
“Partnering with Bionova Scientific allows us to bring the advantages of Syenex’s precise and scalable delivery platforms directly to therapeutic developers through a trusted, high-quality CDMO,” says Jay Rosanelli, CEO and co-founder of Syenex.
